Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2026
Reporting Period: Fourth quarter and transition period ended December 31, 2025.
Key Financial Metrics
The filing serves as a notification of the release of financial results and investor materials. The text of this Form 8-K does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the provided source text.
Material Changes
The filing does not detail specific material changes in financial performance versus prior periods. It solely references the issuance of a press release announcing the consolidated financial results for the period ended December 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company made available an Investor Presentation on its website on March 16, 2026, which is furnished as Exhibit 99.2.
Legal Status of Information: The information in Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD), including the attached exhibits, is furnished and not deemed "filed" under Section 18 of the Exchange Act. Consequently, this information shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and transition period financial figures.
- Examine Exhibit 99.2 (Investor Presentation) for management guidance and strategic outlook.
- Verify the "furnished" status of the data, noting it is not legally "filed" for liability purposes under Section 18 of the Exchange Act.
- Confirm the transition period details ending December 31, 2025, as this may impact year-over-year comparisons.